Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-30

Dynavax Technologies (DVAX)

CEO Ryan Spencer was paid $8,210,775 in fiscal year 2024, ↑ up 41.3% from fiscal year 2023, the 32nd percentile of its disclosed peer group (SEC filing 0000930413-25-001273 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,210,775 ↑
Ryan Spencer total, FY2024
32nd
CEO pay percentile vs peers
—
CEO-to-median pay ratio
92.38%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Ryan Spencer (Chief Executive Officer and Director), FY2024 total compensation $8,210,775 (base salary $835,001) [exec_comp, SEC accession 0000930413-25-001273, filed 2025-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Ryan Spencer$835,001$0$4,902,150$1,824,299$641,907$0$7,418$8,210,775
Chief Executive Officer and Director
David Novack593,10802,016,121750,253364,76207,4433,731,687
President and Chief Operating Officer
John Slebir530,00001,485,500552,818271,62507,5042,847,447
Senior Vice President and General Counsel
Kelly MacDonald480,0986,6421,379,435513,331239,40807,3532,626,267
Senior Vice President and Chief Financial Officer
Robert Janssen542,29101,060,944394,870277,92407,5042,283,533
Chief Medical Officer and Senior Vice President

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Ryan Spencer$8,210,775$5,810,736$5,594,000↑ +2,400,039
David Novack3,731,6872,993,3312,779,823↑ +738,356
John Slebir2,847,447———
Kelly MacDonald2,626,2672,065,8051,793,266↑ +560,462
Robert Janssen2,283,5331,883,3231,710,780↑ +400,210

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Dynavax Technologies's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper DVAX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against DVAX
17 companies name DVAX as a compensation peer

The list of companies that name DVAX as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
John SlebirGeneral Counsel$2,847,447
Kelly MacDonaldCFO$2,626,267
Robert JanssenSVP$2,283,533
Ryan SpencerCEO$8,210,775
David NovackPresident$3,731,687
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Brent MacGregorIndependent Director$285,637
Daniel L. KisnerIndependent Director$297,637
Elaine SunIndependent Director$290,637
Emilio EminiIndependent Director—
Francis R. CanoIndependent Director$285,637
Julie EastlandIndependent Director$300,637
Lauren SilvernailIndependent Director—
Peggy V. PhillipsIndependent Director$305,637
Peter R. ParadisoIndependent Director$302,387
Scott MyersChair of the Board$330,637
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Joseph Anthony MetzingerVP, Chief Accounting Officer2025-05-12A38,182——Derivative, Class A CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2025-05-12A31,500——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2025-06-11A5,75800CommonForm 4 ↗
Francis R. CanoDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Francis R. CanoDirector2025-06-11A5,75800CommonForm 4 ↗
Brent MacGregorDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2025-06-11A5,75800CommonForm 4 ↗
Elaine SunDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Elaine SunDirector2025-06-11A5,75800CommonForm 4 ↗
Emilio EminiDirector2025-06-11A7,12500Derivative, Class A CommonForm 4 ↗
Emilio EminiDirector2025-06-11A1,43900CommonForm 4 ↗
Peter R. ParadisoDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Peter R. ParadisoDirector2025-06-11A5,75800CommonForm 4 ↗
Daniel L. KisnerDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2025-06-11A5,75800CommonForm 4 ↗
Lauren SilvernailDirector2025-06-11A7,12500Derivative, Class A CommonForm 4 ↗
Lauren SilvernailDirector2025-06-11A1,43900CommonForm 4 ↗
Scott MyersDirector2025-06-11A28,50000Derivative, Class A CommonForm 4 ↗
Deep Track Biotechnology Master Fund, Ltd.Greater-than-10% holder2025-08-21D1,094,9941112,077,784CommonForm 4 ↗
Deep Track Biotechnology Master Fund, Ltd.Greater-than-10% holder2025-08-22D970,1431110,273,814CommonForm 4 ↗
Scott MyersDirector2025-08-22A3,8001141,116CommonForm 4 ↗
David NovackPresident & COO2025-12-23D22,620——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-12-23D55,000——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-23A16,667——CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-23A33,750——CommonForm 4 ↗
David NovackPresident & COO2025-12-23A18,788——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-23D15,477——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-23A14,141——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-23A15,477——CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2025-12-23D12,727——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-12-23D45,333——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-12-23A156,250——CommonForm 4 ↗
David NovackPresident & COO2025-12-23A22,620——CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-23D16,667——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2025-12-23A60,625——CommonForm 4 ↗
Ryan SpencerDirector2025-12-23A45,333——CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2025-12-23A12,727——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-23D14,141——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2025-12-23D18,788——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-12-23A55,000——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-23A37,500——CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-23A14,141——CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-23D14,141——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-12-24D138,168152,125,024CommonForm 4 ↗
John SlebirSVP General Counsel2025-12-24D32,50215499,881CommonForm 4 ↗
David NovackPresident & COO2025-12-24D48,10715739,886CommonForm 4 ↗
David NovackPresident & COO2025-12-24A10,00010104,700CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2025-12-24D5,5981586,097CommonForm 4 ↗
David NovackPresident & COO2025-12-24A20,0007136,100CommonForm 4 ↗
David NovackPresident & COO2025-12-24D10,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2025-12-24D20,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2025-12-24D30,00015464,700CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2025-12-24D36,14115555,849CommonForm 4 ↗
David NovackPresident & COO2026-01-15D85,655——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-01-15D114,000161,782,960Common, open-market saleForm 4 ↗
David NovackPresident & COO2026-01-15D8,345——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-01-15D20,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-01-15A94,00010984,180CommonForm 4 ↗
David NovackPresident & COO2026-01-15A20,0007136,100CommonForm 4 ↗
David NovackPresident & COO2026-02-10D37,576——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D22,620——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D93,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D150,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D150,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D56,364——CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Lauren SilvernailDirector2026-02-10D42,750——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D25,000——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D50,000——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D21,829——CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D28,500——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D25,000——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D15,000——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D1,500——CommonForm 4 ↗
Elaine SunDirector2026-02-10D28,500——Derivative, Class A CommonForm 4 ↗
Elaine SunDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Elaine SunDirector2026-02-10D11,250——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2026-02-10D28,500——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2026-02-10D16,875——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2026-02-10D45,000——Derivative, Class A CommonForm 4 ↗
Scott MyersDirector2026-02-10D31,204——CommonForm 4 ↗
Scott MyersDirector2026-02-10D3,800——CommonForm 4 ↗
Emilio EminiDirector2026-02-10D42,750——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D70,000——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D350,000——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D46,430——CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2026-02-10D25,455——Derivative, Class A CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2026-02-10D7,129——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D28,283——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D16,666——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D88,000——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10A42,424——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D69,634——CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D55,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D225,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D250,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D400,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10A136,000——CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D379,620——CommonForm 4 ↗
David NovackPresident & COO2026-02-10A56,364——CommonForm 4 ↗
David NovackPresident & COO2026-02-10D63,334——CommonForm 4 ↗
David NovackPresident & COO2026-02-10A67,860——CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D25,000——Derivative, Class A CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D25,000——Derivative, Class A CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D42,663——CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D25,000——Derivative, Class A CommonForm 4 ↗
Daniel L. KisnerDirector2026-02-10D21,829——CommonForm 4 ↗
Elaine SunDirector2026-02-10D45,000——Derivative, Class A CommonForm 4 ↗
Elaine SunDirector2026-02-10D29,865——CommonForm 4 ↗
Scott MyersDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D90,500——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D70,000——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D80,000——Derivative, Class A CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D42,424——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D50,000——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10A50,000——CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D280,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D165,000——CommonForm 4 ↗
Deep Track Biotechnology Master Fund, Ltd.Greater-than-10% holder2026-02-10D15,726,349——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D70,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D130,000——Derivative, Class A CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D150,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D67,860——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D42,424——CommonForm 4 ↗
Emilio EminiDirector2026-02-10D7,125——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D350,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D95,000——Derivative, Class A CommonForm 4 ↗
David NovackPresident & COO2026-02-10D150,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D90,667——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D231,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D50,000——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-02-10D136,000——CommonForm 4 ↗
Ryan SpencerDirector2026-02-10A165,000——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D65,000——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D100,000——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10A42,424——CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D28,283——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D15,476——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10A46,430——CommonForm 4 ↗
Emilio EminiDirector2026-02-10D10,075——CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Francis R. CanoDirector2026-02-10D28,500——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Brent MacGregorDirector2026-02-10D28,500——Derivative, Class A CommonForm 4 ↗
Lauren SilvernailDirector2026-02-10D7,125——Derivative, Class A CommonForm 4 ↗
Lauren SilvernailDirector2026-02-10D10,075——CommonForm 4 ↗
John SlebirSVP General Counsel2026-02-10D300,000——Derivative, Class A CommonForm 4 ↗
Elaine SunDirector2026-02-10D22,500——Derivative, Class A CommonForm 4 ↗
Kelly MacDonaldSVP and CFO2026-02-10D60,204——CommonForm 4 ↗
Joseph Anthony MetzingerVP, Chief Accounting Officer2026-02-10D31,500——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Robert JanssenOPTION2024-02-15——50,000—$394,870
David NovackOPTION2024-02-15——95,000—750,253
John SlebirOPTION2024-02-15——70,000—552,818
Ryan SpencerPSU2024-02-1582,500165,000—330,0002,842,950
Kelly MacDonaldPSU2024-02-1523,21546,430—92,860799,989
Robert Janssen—2024-02-15——35,710—445,661
David Novack—2024-02-15——67,860—846,893
Kelly MacDonald—2024-02-15——46,430—579,446
Ryan Spencer—2024-02-15——165,000—2,059,200
John Slebir—2024-02-15——50,000—624,000
David NovackPSU2024-02-1533,93067,860—135,7201,169,228
John SlebirPSU2024-02-1525,00050,000—100,000861,500
Kelly MacDonaldOPTION2024-02-15——65,000—513,331
Ryan SpencerOPTION2024-02-15——231,000—1,824,299
Robert JanssenPSU2024-02-1517,85535,710—71,420615,283
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Robert Janssen$0$615,283$394,87060.9%
David Novack01,169,228750,25360.9%
John Slebir0861,500552,81860.9%
Ryan Spencer02,842,9501,824,29960.9%
Kelly MacDonald0799,989513,33160.9%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
John SlebirPSU27,000—$344,790
David NovackRSU67,860—866,572
Kelly MacDonaldPSU46,430—592,911
Robert JanssenPSU35,710—456,017
Robert JanssenRSU35,710—456,017
Ryan SpencerPSU165,000—2,107,050
David NovackPSU67,860—866,572
John SlebirOption34,22211.12—
Ryan SpencerOption108,89011.12—
John SlebirRSU4,666—59,585
John SlebirOption70,00012.48—
Ryan SpencerPSU62,500—798,125
Kelly MacDonaldOption5,02812.74—
John SlebirPSU14,000—178,780
Ryan SpencerRSU20,833—266,037
David NovackPSU26,500—338,405
Kelly MacDonaldPSU16,000—204,320
Robert JanssenPSU24,000—306,480
Kelly MacDonaldRSU5,333—68,102
Ryan SpencerOption231,00012.48—
Robert JanssenRSU4,333—55,332
Kelly MacDonaldOption65,00012.48—
David NovackOption95,00012.48—
Ryan SpencerRSU165,000—2,107,050
John SlebirRSU50,000—638,500
David NovackRSU8,833—112,797
Robert JanssenOption4,16712.74—
John SlebirOption4,44512.74—
Kelly MacDonaldRSU46,430—592,911
Robert JanssenOption31,11111.12—
John SlebirPSU50,000—638,500
Ryan SpencerPSU125,000—1,596,250
Kelly MacDonaldPSU30,000—383,100
David NovackPSU48,500—619,345
Robert JanssenPSU13,000—166,010
Ryan SpencerOption19,44512.74—
Kelly MacDonaldOption38,89011.12—
David NovackOption58,33411.12—
David NovackOption8,33412.74—
Robert JanssenOption50,00012.48—
05

Incentive-plan design — the Compensation Discussion & Analysis

We believe our NEOs' compensation should align our executives' interests with that of our stockholders over the long-term through achievement of strategic corporate objectives that are fundamental to our business and that are intended to create long-term stockholder value. Our executive compensation programs are designed to be competitive within our industry and within our peer group to enable us to attract, motivate, reward, and retain outstanding talent.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)—
Independent consultantAlpine
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-1188,358,5857,283,834938,87192.38%Passed
20242024-04-1188,138,4683,105,543232,29196.35%Passed
20232023-05-2676,588,2706,298,635403,75692.4%Passed
20222022-04-0467,697,5744,551,027272,28593.7%Passed
20212021-04-0652,481,0772,483,790268,27495.02%Passed
20202020-05-2846,279,8813,848,208201,99191.95%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-1192.38%a
20242024-04-1196.35%b
20232023-05-2692.4%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Abstentions have the same effect as negative votes.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Scott MyersIndependent · Board Chair · Compensation (Chair)$100,000$63,480$167,157$0$0$330,637
Peggy V. PhillipsIndependent · Audit · Compensation (Chair) · Not standing for re-election75,00063,480167,15700305,637
Peter R. ParadisoIndependent · Compensation71,75063,480167,15700302,387
Julie EastlandIndependent · Audit (Chair) · Not standing for re-election70,00063,480167,15700300,637
Daniel L. KisnerIndependent · Nominating/Governance (Chair) · Compensation67,00063,480167,15700297,637
Elaine SunIndependent · Audit60,00063,480167,15700290,637
Brent MacGregorIndependent · Nominating/Governance55,00063,480167,15700285,637
Francis R. CanoIndependent · Nominating/Governance55,00063,480167,15700285,637
Lauren SilvernailIndependent · Audit (Chair) · Newly elected000000
Ryan SpencerEmployee director000000
Emilio EminiIndependent · Newly elected000000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$553,750
Equity awards (grant-date value)$507,840
All other compensation$0
Total cost of the board$1,061,590

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Dynavax Technologies names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Dynavax Technologies.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2PTC Therapeutics, Inc.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
3Supernus Pharmaceuticals, Inc.2025Jack Khattar1,036,0006,535,0297,031,545846,93015,501,557
4Corcept Therapeutics, Inc.2025Joseph Belanoff1,182,333012,907,718015,303,551
5Vaxcyte, Inc.2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
6Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
7Pacira BioSciences, Inc.2025Frank Lee935,3089,215,5000738,81011,636,917
8Eagle Pharmaceuticals, Inc.2022Scott Tarriff848,9409,011,1970636,70510,520,577
9Mannkind Corp.2025Michael Castagna789,4367,689,4800675,7579,300,485
10Novavax, Inc.2025John Jacobs792,9173,545,4353,763,292640,3318,856,015
11Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
12Travere Therapeutics, Inc.2025Eric Dube854,2503,314,5203,309,384964,1258,457,151
13Acadia Pharmaceuticals, Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
14Dynavax Technologies2024Ryan Spencer835,0014,902,1501,824,299641,9078,210,775
15Harmony Biosciences, Inc.2025Jeffrey Dayno743,6001,976,5204,599,000558,0007,899,535
16Vir Biotechnology, Inc.2025Marianne De Backer950,0002,296,8003,507,3601,002,7507,834,045
17Alector, Inc.2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
18Ironwood Pharmaceuticals, Inc.2025Thomas McCourt867,568411,6960650,6761,948,390
19Collegium Pharmaceuticals, Inc.2025Vikram Karnani875,00000835,4061,715,846
20Agenus, Inc.2025Garo Armen715,2600141,00001,350,325

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Dynavax Technologies102.5%Options 34 · RSU 33 · PSU 33Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology IndexAlpine
Acadia Pharmaceuticals, Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Agenus, Inc.125%Options 100not disclosedAon Radford
Alector, Inc.80%not disclosednot disclosedPearl Meyer & Partners, LLC
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Collegium Pharmaceuticals, Inc.127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Corcept Therapeutics, Inc.Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Eagle Pharmaceuticals, Inc.75%PSU 75 · RSU 25Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR)Compensia
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Harmony Biosciences, Inc.100%not disclosednot disclosedPay Governance
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Ironwood Pharmaceuticals, Inc.100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Mannkind Corp.107%PSU 55 · RSU 45Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology IndexMercer LLC
Novavax, Inc.95%Options 50 · RSU 50not disclosedPearl Meyer
Pacira BioSciences, Inc.90%RSU 80 · PSU 20NoAon
PTC Therapeutics, Inc.not disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Supernus Pharmaceuticals, Inc.not disclosednot disclosedNoAon
Travere Therapeutics, Inc.150%not disclosedNoAon
Vaxcyte, Inc.105%not disclosednot disclosedPay Governance
Vir Biotechnology, Inc.125%Options 67 · RSU 33not disclosedSemler Brossy

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Dynavax Technologies in fiscal 2024?
As disclosed, Ryan Spencer (Chief Executive Officer and Director) was the highest-paid executive at Dynavax Technologies in fiscal 2024, with total compensation of $8,210,775.
How does Dynavax Technologies's chief executive pay compare to its disclosed peer group?
As disclosed, Ryan Spencer's total compensation ranked at the 32nd percentile of Dynavax Technologies's disclosed peer group.
How did shareholders vote on Dynavax Technologies's executive compensation?
As disclosed, 92.38% of shareholders supported Dynavax Technologies's executive compensation in the latest say-on-pay vote.
How much does Dynavax Technologies spend in total on board compensation for fiscal 2024?
As disclosed, Dynavax Technologies reported total board compensation of $1,061,590 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Ryan SpencerDEF 14A2025-04-170000930413-25-001273Section “Executive Compensation”. As printed: 8,210,775. Filing ↗
2Section 01, David NovackDEF 14A2025-04-170000930413-25-001273Section “Executive Compensation”. As printed: 3,731,687. Filing ↗
3Section 01, John SlebirDEF 14A2025-04-170000930413-25-001273Section “Executive Compensation”. As printed: 2,847,447. Filing ↗
4Section 01, Kelly MacDonaldDEF 14A2025-04-170000930413-25-001273Section “Executive Compensation”. As printed: 2,626,267. Filing ↗
5Section 01, Robert JanssenDEF 14A2025-04-170000930413-25-001273Section “Executive Compensation”. As printed: 2,283,533. Filing ↗
6Section 03, Robert Janssen OPTIONDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
7Section 03, David Novack OPTIONDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
8Section 03, John Slebir OPTIONDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
9Section 03, Ryan Spencer PSUDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
10Section 03, Kelly MacDonald PSUDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
11Section 03, Robert Janssen DEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
12Section 03, David Novack DEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
13Section 03, Kelly MacDonald DEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
14Section 03, Ryan Spencer DEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
15Section 03, John Slebir DEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
16Section 03, David Novack PSUDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
17Section 03, John Slebir PSUDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
18Section 03, Kelly MacDonald OPTIONDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
19Section 03, Ryan Spencer OPTIONDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
20Section 03, Robert Janssen PSUDEF 14A——Section “Executive Compensation” · grants of plan-based awards table.
21Section 08, Scott MyersDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 330,637. Filing ↗machine: t119 · r1 · c15 · span 345275–345282
22Section 08, Peggy V. PhillipsDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 305,637. Filing ↗machine: t119 · r7 · c15 · span 357174–357181
23Section 08, Peter R. ParadisoDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 302,387. Filing ↗machine: span 355197–355204
24Section 08, Julie EastlandDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 300,637. Filing ↗machine: t119 · r3 · c15 · span 349242–349249
25Section 08, Daniel L. KisnerDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 297,637. Filing ↗machine: span 351224–351231
26Section 08, Elaine SunDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 290,637. Filing ↗machine: t119 · r8 · c15 · span 359144–359151
27Section 08, Brent MacGregorDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 285,637. Filing ↗machine: t119 · r5 · c15 · span 353199–353206
28Section 08, Francis R. CanoDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 285,637. Filing ↗machine: span 347268–347275
29Section 08, Lauren SilvernailDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 0. Filing ↗
30Section 08, Ryan SpencerDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 0. Filing ↗
31Section 08, Emilio EminiDEF 14A2025-04-170000930413-25-001273Section “Director Compensation”. As printed: 0. Filing ↗
32Section 02, Joseph Anthony Metzinger 2025-05-12Form 42025-05-130001029142-25-000085Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Joseph Anthony Metzinger 2025-05-12Form 42025-05-130001029142-25-000085Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Scott Myers 2025-06-11Form 42025-06-130001029142-25-000102Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Francis R. Cano 2025-06-11Form 42025-06-130001029142-25-000091Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Francis R. Cano 2025-06-11Form 42025-06-130001029142-25-000091Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Brent MacGregor 2025-06-11Form 42025-06-130001029142-25-000093Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Brent MacGregor 2025-06-11Form 42025-06-130001029142-25-000093Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Elaine Sun 2025-06-11Form 42025-06-130001029142-25-000095Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Elaine Sun 2025-06-11Form 42025-06-130001029142-25-000095Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Emilio Emini 2025-06-11Form 42025-06-130001029142-25-000098Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Emilio Emini 2025-06-11Form 42025-06-130001029142-25-000098Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Peter R. Paradiso 2025-06-11Form 42025-06-130001029142-25-000100Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Peter R. Paradiso 2025-06-11Form 42025-06-130001029142-25-000100Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Daniel L. Kisner 2025-06-11Form 42025-06-130001029142-25-000104Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Daniel L. Kisner 2025-06-11Form 42025-06-130001029142-25-000104Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Lauren Silvernail 2025-06-11Form 42025-06-130001029142-25-000106Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Lauren Silvernail 2025-06-11Form 42025-06-130001029142-25-000106Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Scott Myers 2025-06-11Form 42025-06-130001029142-25-000102Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-21Form 42025-08-220000950170-25-111070Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-22Form 42025-08-220000950170-25-111070Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Scott Myers 2025-08-22Form 42025-08-250001029142-25-000120Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, David Novack 2025-12-23Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Ryan Spencer 2025-12-23Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, John Slebir 2025-12-23Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, John Slebir 2025-12-23Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, David Novack 2025-12-23Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Kelly MacDonald 2025-12-23Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Kelly MacDonald 2025-12-23Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Kelly MacDonald 2025-12-23Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Joseph Anthony Metzinger 2025-12-23Form 42025-12-290001628280-25-058989Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Ryan Spencer 2025-12-23Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Ryan Spencer 2025-12-23Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, David Novack 2025-12-23Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, John Slebir 2025-12-23Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, David Novack 2025-12-23Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Ryan Spencer 2025-12-23Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Joseph Anthony Metzinger 2025-12-23Form 42025-12-290001628280-25-058989Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Kelly MacDonald 2025-12-23Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, David Novack 2025-12-23Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Ryan Spencer 2025-12-23Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Kelly MacDonald 2025-12-23Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, John Slebir 2025-12-23Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, John Slebir 2025-12-23Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Ryan Spencer 2025-12-24Form 42025-12-290001628280-25-058969Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, John Slebir 2025-12-24Form 42025-12-290001628280-25-058979Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Joseph Anthony Metzinger 2025-12-24Form 42025-12-290001628280-25-058989Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, David Novack 2025-12-24Form 42025-12-290001628280-25-058985Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Kelly MacDonald 2025-12-24Form 42025-12-290001628280-25-058992Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, David Novack 2026-01-15Form 42026-01-200001628280-26-002640Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Lauren Silvernail 2026-02-10Form 42026-02-100001225755-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Emilio Emini 2026-02-10Form 42026-02-100002054163-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Joseph Anthony Metzinger 2026-02-10Form 42026-02-100002067729-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Joseph Anthony Metzinger 2026-02-10Form 42026-02-100002067729-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Daniel L. Kisner 2026-02-10Form 42026-02-100001073407-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Scott Myers 2026-02-10Form 42026-02-100001356256-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Deep Track Biotechnology Master Fund, Ltd. 2026-02-10Form 42026-02-110001193125-26-046675Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Emilio Emini 2026-02-10Form 42026-02-100002054163-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, David Novack 2026-02-10Form 42026-02-100001573072-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Ryan Spencer 2026-02-10Form 42026-02-100001777938-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Emilio Emini 2026-02-10Form 42026-02-100002054163-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Francis R. Cano 2026-02-10Form 42026-02-100001286710-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Brent MacGregor 2026-02-10Form 42026-02-100001818951-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Lauren Silvernail 2026-02-10Form 42026-02-100001225755-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Lauren Silvernail 2026-02-10Form 42026-02-100001225755-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, John Slebir 2026-02-10Form 42026-02-100001475990-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Elaine Sun 2026-02-10Form 42026-02-100001805339-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Kelly MacDonald 2026-02-10Form 42026-02-100001781117-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Joseph Anthony Metzinger 2026-02-10Form 42026-02-100002067729-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
189Section 06, 2025 voteForm 8-K2025-06-170001193125-25-141755Item 5.07 · say-on-pay result. As reported: 92.38% (votes for as printed: 88,358,585). Filing ↗
190Section 06, 2024 voteForm 8-K2024-05-240000950170-24-064556Item 5.07 · say-on-pay result. As reported: 96.35% (votes for as printed: 88,138,468). Filing ↗
191Section 06, 2023 voteForm 8-K2023-05-260000950170-23-024566Item 5.07 · say-on-pay result. As reported: 92.4% (votes for as printed: 76,588,270). Filing ↗
192Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
193Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
194Section 09b board cost (computed)Computed——Cash 553,750 + equity 507,840 + all other 0 = 1,061,590, summed across the director compensation table rows.machine: formula: Σ = 1,061,590
195Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
196PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗
197Supernus Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-300001104659-26-053111CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604
198Corcept Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics, Inc.'s own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
199Vaxcyte, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173672CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207
200Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
201Pacira BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
202Eagle Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2023-05-010001104659-23-054338CEO total compensation as printed in Eagle Pharmaceuticals, Inc.'s own proxy. As printed: 10,520,577. Filing ↗machine: r1 · c47 · span 689556–689566
203Mannkind Corp., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145613CEO total compensation as printed in Mannkind Corp.'s own proxy. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621
204Novavax, Inc., Section 10b CEO totalDEF 14A2026-04-270001628280-26-027328CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394
205Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
206Travere Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-060001438533-26-000027CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523
207Acadia Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in Acadia Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗
208Dynavax Technologies (subject), Section 10b CEO totalDEF 14A2025-04-170000930413-25-001273CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗
209Harmony Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-030001104659-26-039449CEO total compensation as printed in Harmony Biosciences, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364
210Vir Biotechnology, Inc., Section 10b CEO totalDEF 14A2026-04-160001628280-26-025379CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922
211Alector, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
212Ironwood Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
213Collegium Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceuticals, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
214Agenus, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197536CEO total compensation as printed in Agenus, Inc.'s own proxy. As printed: 1,350,325. Filing ↗machine: r2 · c21 · span 404620–404629
215Section 10a, Alector, Inc. reciprocityDEF 14A—0001193125-26-186928Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
216Section 10a, Agenus, Inc. reciprocityDEF 14A—0001193125-26-197536Agenus, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
217Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
218Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
219Section 10a, Supernus Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-053111Supernus Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗
220Section 10a, Collegium Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-024063Collegium Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
221Section 10a, Travere Therapeutics, Inc. reciprocityDEF 14A—0001438533-26-000027Travere Therapeutics, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗
222Section 10a, Ironwood Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
223Section 10a, Vaxcyte, Inc. reciprocityDEF 14A—0001193125-26-173672Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
224Section 10a, Mannkind Corp. reciprocityDEF 14A—0001193125-26-145613Mannkind Corp.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
225Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
226Section 10a, Harmony Biosciences, Inc. reciprocityDEF 14A—0001104659-26-039449Harmony Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
227Section 10a, Eagle Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-23-054338Eagle Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
228Section 10a, Pacira BioSciences, Inc. reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗
229Section 10a, Acadia Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-174163Acadia Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗
230Section 10a, Novavax, Inc. reciprocityDEF 14A—0001628280-26-027328Novavax, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗
231Section 10a, Vir Biotechnology, Inc. reciprocityDEF 14A—0001628280-26-025379Vir Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗
232Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.